oxb.com

What It Is

OXB is a global cell and gene therapy CDMO headquartered in Oxford, UK, with roots traceable to an Oxford University spin-out project. Its official website highlights around 30 years of experience in viral vectors. It is important to note that oxb.com is not a SaaS or enterprise software website, but a biopharmaceutical contract development and manufacturing service provider. Its core customers are pharmaceutical companies, biotech firms, and gene therapy startups.

Core Capabilities

OXB’s services span from preclinical development to commercialization, including process development, GMP manufacturing, analytical methods, and regulatory support. Its vector capabilities include lentiviral vectors, AAV, adenoviral vectors, and other viral vectors such as MVA. Its lentiviral platform emphasizes 30 years of manufacturing experience and scalability from 50L to 1000L. For AAV, the site mentions the inAAVate™ platform, which can help customers enter GMP manufacturing in as little as 7 months, and claims high yields and a 90% full capsid ratio in 500L bioreactors. The company also offers three main collaboration models: platform programs, customized solutions, and technology transfer.

Pricing and Collaboration Model

The official website does not disclose standard pricing, packages, or payment methods, which is consistent with the project-based, custom-quote nature of the CDMO industry. One notable offering is the VectorXcellerator program: applications are free, and selected early-stage projects may receive a feasibility study fully funded by OXB, though this does not guarantee any subsequent commercial partnership.

Pros and Cons

Its strengths include multi-vector technology coverage, end-to-end services, a network of GMP facilities in the UK, France, and the US, as well as regulatory support for filings such as IND and MAA and regulatory assets such as FDA DMFs. In the adenoviral vector field, it also references large-scale manufacturing experience from the Oxford–AstraZeneca COVID-19 vaccine. Its limitations are that the service is highly specialized, the information disclosed is more commercially oriented, and there is limited transparency around specific capacity, delivery SLAs, and pricing. Common software-related evaluation criteria in this category—such as integrations, permissions, APIs, and cloud deployment—are largely not applicable.

Who It’s For and Access from China

OXB is suitable for biopharmaceutical companies with cell or gene therapy candidates that need viral vector development, GMP batch manufacturing, technology transfer, or commercial supply chain support. The source text does not provide information on access from mainland China, so this is considered unknown.